Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma

Nature Reviews Clinical Oncology

Volumn 10, Issue 7, 2013, Pages 390-399

  Gibney, Geoffrey T ^a   Messina, Jane L ^b   Fedorenko, Inna V ^a   Sondak, Vernon K ^a   Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CHIR 265; CYCLOOXYGENASE 2; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SORAFENIB; TRAMETINIB; VEMURAFENIB; XL 281;

ADVERSE OUTCOME; ARTHRALGIA; CANCER PREVENTION; CARCINOGENESIS; COLON ADENOMA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MELANOMA; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SEBORRHEIC KERATOSIS; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMACH POLYP;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MELANOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84879795966     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.83     Document Type: Review

References (95)

1. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
2. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
3. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
4. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
5. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
6. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
7. Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003).
8. Tol, J., Nagtegaal, I. D. & Punt, C. J. A. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98-99 (2009).
9. Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
10. Fedorenko, I. V., Paraiso, K. H. & Smalley, K. S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82, 201-209 (2011).
11. Klein, R. M. & Aplin, A. E. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res. 69, 2224-2233 (2009).
12. Cartlidge, R. A. et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 21, 534-544 (2008).
13. Paraiso, K. H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730 (2010).
14. Shao, Y. & Aplin, A. E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681 (2010).
15. Arozarena, I. et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19, 45-57 (2011).
16. Haass, N. K. et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 14, 230-239 (2008).
17. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
18. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
19. Long, G. V. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246 (2011).
20. Menzies, A. M., Long, G. V. & Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther. 6, 391-405 (2012).
21. Greger, J. G. et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920 (2012).
22. Kirkwood, J. M. et al. Phase II, open-label, randomized trial of the MEK 1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567 (2012).
23. Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256 (2013).
24. Robert, C. et al. METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM) [abstract]. J. Clin. Oncol. 30 (Suppl.), LBA8509 (2012).
25. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
26. Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901 (2012).
27. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
28. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
29. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
30. Shi, H. B. et al. Melanoma whole-exome sequencing identifies B-V600E-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
31. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682 (2012).
32. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
33. Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200 (2010).
34. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
35. Kaplan, F. M., Shao, Y., Mayberry, M. M. & Aplin, A. E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the ongenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cell lines. Oncogene 30, 366-371 (2010).
36. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465 (2003).
37. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell. Biol. 5, 875-885 (2004).
38. Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996).
39. Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005).
40. Cho, K. J. et al. Raf Inhibitors target ras spatiotemporal dynamics. Curr. Biol. 22, 945-955 (2012).
41. Zang, M. W. et al. Characterization of Ser338 phosphorylation for Raf-1 activation. J. Biol. Chem. 283, 31429-31437 (2008).
42. Baljuls, A., Kholodenko, B. N. & Kolch, W. It takes two to tango-signalling by dimeric Raf kinases. Mol. Biosyst. 9, 551-558 (2013).
43. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
44. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262-2272 (2006).
45. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
46. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
47. Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908 (2010).
48. Keefe, D. M. & Bateman, E. H. Tumor control versus adverse events with targeted anticancer therapies. Nat. Rev. Clin. Oncol. 9, 98-109 (2012).
49. Anforth, R., Fernandez-Penas, P. & Long, G. V. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 14, e11-e18 (2013).
50. Anforth, R. M. et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167, 1153-1160 (2012).
51. Lacouture, M. E. et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18, 314-322 (2013).
52. Robert, C., Mateus, C., Spatz, A., Wechsler, J. & Escudier, B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J. Am. Acad. Dermatol. 60, 299-305 (2009).
53. Rinderknecht, J. D. et al. RASopathic skin eruptions during vemurafenib therapy. PLoS ONE 8, e58721 (2013).
54. Ravanat, J. L., Douki, T. & Cadet, J. Direct and indirect effects of UV radiation on DNA and its components. J. Photochem. Photobiol. B. 63, 88-102 (2001).
55. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
56. Oberholzer, P. A. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321 (2012).
57. Zimmer, L. et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30, 2375-2383 (2012).
58. Dalle, S., Poulalhon, N. & Thomas, L. Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 365, 1448-1449 (2011).
59. Callahan, M. K. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321 (2012).
60. Andrews, M. et al. Colorectal cancer promoted in a patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212) [abstract]. Pigment Cell Melanoma Res. 25, 842 (2012).
61. Kim, K. et al. Significant long-term survival benefit demonstrated with vemurafenib in ongoing phase I study. Pigment Cell Melanoma Res. 25, 866 (2012).
62. Chapman, P. B. et al. Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res. 25, 847 (2012).
63. Heitman, S. J. et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 7, 1272-1278 (2009).
64. Carmack, S. W., Genta, R. M., Schuler, C. M. & Saboorian, M. H. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am. J. Gastroenterol. 104, 1524-1532 (2009).
65. Carmack, S. W., Genta, R. M., Graham, D. Y. & Lauwers, G. Y. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat. Rev. Gastroenterol. Hepatol. 6, 331-341 (2009).
66. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
67. Kressner, U. et al. Ki-ras mutations and prognosis in colorectal cancer. Eur. J. Cancer 34, 518-521 (1998).
68. Brink, M. et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24, 703-710 (2003).
69. Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103, 311-320 (2000).
70. Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804 (1997).
71. Ikeda, S. et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17, 1371-1384 (1998).
72. Lee, S. H. et al. ERK activation drives intestinal tumorigenesis in Apcmin/+ mice. Nat. Med. 16, 665-670 (2010).
73. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
74. Turke, A. B. et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228-3237 (2012).
75. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
76. Abel, E. V. et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168 (2013).
77. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01584648 (2013).
78. Le, K., Blomain, E. & Aplin, A. E. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistance melanoma cells. Pigment Cell Melanoma Res. http://dx.doi.org/10.1111/pcmr.12092.
79. Anforth, R., Blumetti, T. C., Mohd Affandi, A. & Fernandez-Penas, P. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J. Clin. Oncol. 30, e165-e167 (2012).
80. Lien, M. H., Fenske, N. A. & Glass, L. F. Advances in the chemoprevention of non-melanoma skin cancer in high-risk organ transplant recipients. Semin. Oncol. 39, 134-138 (2012).
81. Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R. & Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6, 793-810 (2007).
82. Escuin-Ordinas, H. et al. COX2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Pigment Cell Melanoma Res. 25, 854 (2012).
83. An, K. P. et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem. Photobiol. 76, 73-80 (2002).
84. Pentland, A. P., Schoggins, J. W., Scott, G. A., Khan, K. N. & Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20, 1939-1944 (1999).
85. Burns, E. M. et al. Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma. Carcinogenesis 34, 370-377 (2013).
86. Elmets, C. A. et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J. Natl Cancer Inst. 102, 1835-1844 (2010).
87. Bertagnolli, M. M. et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. 2, 310-321 (2009).
88. Arber, N. & Moshkowitz, M. Small bowel polyposis syndromes. Curr. Gastroenterol. Rep. 13, 435-441 (2011).
89. Harach, H. R., Franssila, K. O. & Wasenius, V. M. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56, 531-538 (1985).
90. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
91. Delongchamps, N. B., de la Roza, G., Jones, R., Jumbelic, M. & Haas, G. P. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 103, 49-54 (2009).
92. Ling, G. et al. Persistent p53 mutations in single cells from normal human skin. Am. J. Pathol. 159, 1247-1253 (2001).
93. Smalley, K. S. & Sondak, V. K. Skin cancer: Targeted therapy for melanoma: is double hitting a home run? Nat. Rev. Clin. Oncol. 10, 5-6 (2013).
94. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01667419 (2013).
95. Ding, Q. et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 19, 159-170 (2005).